Compare DOMH & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | FBIO |
|---|---|---|
| Founded | 1967 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 88.7M |
| IPO Year | N/A | N/A |
| Metric | DOMH | FBIO |
|---|---|---|
| Price | $3.97 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 265.7K | ★ 339.4K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | ★ 14.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.19 | N/A |
| Revenue | ★ $99,588,000.00 | $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | $0.42 | ★ N/A |
| Revenue Growth | ★ 691.07 | N/A |
| 52 Week Low | $0.83 | $1.33 |
| 52 Week High | $13.58 | $4.20 |
| Indicator | DOMH | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 61.14 |
| Support Level | $3.73 | $2.49 |
| Resistance Level | $5.00 | $2.86 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 19.22 | 90.20 |
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.